Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Holmes, Michael V.; Simon, Tabassome; Exeter, Holly J.; Folkersen, Lasse; Asselbergs, Folkert W.; Guardiola, Montse; Cooper, Jackie A.; Palmen, Jutta; Hubacek, Jaroslav A.; Carruthers, Kathryn F.; Horne, Benjamin D.; Brunisholz, Kimberly D.; Mega, Jessica L.; van Iperen, Erik P.A.; Li, Mingyao; Leusink, Maarten; Trompet, Stella; Verschuren, Jeffrey J.W.; Hovingh, G. Kees; Dehghan, Abbas; Nelson, Christopher P.; Kotti, Salma; Danchin, Nicolas; Scholz, Markus; Haase, Christiane L.; Rothenbacher, Dietrich; Swerdlow, Daniel I.; Kuchenbaecker, Karoline B.; Staines-Urias, Eleonora; Goel, Anuj ... view all 113 authors View less authors (2013)
Publisher: Elsevier Biomedical
Journal: Journal of the American College of Cardiology
Languages: English
Types: Article
Subjects: MI, myocardial infarction, OR, odds ratio, LDL-C, low-density lipoprotein cholesterol, ARTERY-DISEASE, RCT, randomized clinical trial, Cardiology and Cardiovascular Medicine, SERUM-LEVELS, EPIC-NORFOLK, ACUTE CORONARY SYNDROMES, TRIAL, epidemiology, genetics, INHIBITOR, MVE, major vascular events, EVENTS, Cardiometabolic Risk, SNP, single-nucleotide polymorphism, drug development, sPLA2, secretory phospholipase A2, cardiovascular diseases, CI, confidence interval, ACS, acute coronary syndrome(s), Clinical Research, RISK, Mendelian randomization, HEALTHY-MEN
Objectives:\ud This study sought to investigate the role of secretory phospholipase A2 (sPLA2)-IIA in cardiovascular disease.

\ud \ud Background:\ud Higher circulating levels of sPLA2-IIA mass or sPLA2 enzyme activity have been associated with increased risk of cardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2 inhibitor (varespladib) was stopped prematurely for lack of efficacy.

\ud \ud Methods:\ud We conducted a Mendelian randomization meta-analysis of 19 general population studies (8,021 incident, 7,513 prevalent major vascular events [MVE] in 74,683 individuals) and 10 acute coronary syndrome (ACS) cohorts (2,520 recurrent MVE in 18,355 individuals) using rs11573156, a variant in PLA2G2A encoding the sPLA2-IIA isoenzyme, as an instrumental variable.

\ud \ud Results:\ud PLA2G2A rs11573156 C allele associated with lower circulating sPLA2-IIA mass (38% to 44%) and sPLA2 enzyme activity (3% to 23%) per C allele. The odds ratio (OR) for MVE per rs11573156 C allele was 1.02 (95% confidence interval [CI]: 0.98 to 1.06) in general populations and 0.96 (95% CI: 0.90 to 1.03) in ACS cohorts. In the general population studies, the OR derived from the genetic instrumental variable analysis for MVE for a 1-log unit lower sPLA2-IIA mass was 1.04 (95% CI: 0.96 to 1.13), and differed from the non-genetic observational estimate (OR: 0.69; 95% CI: 0.61 to 0.79). In the ACS cohorts, both the genetic instrumental variable and observational ORs showed a null association with MVE. Instrumental variable analysis failed to show associations between sPLA2 enzyme activity and MVE.

\ud \ud Conclusions:\ud Reducing sPLA2-IIA mass is unlikely to be a useful therapeutic goal for preventing cardiovascular events.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J 2012;33:2899-909.
    • 2. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010;122:2183-200.
    • 3. Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005;46:1249-57.
    • 4. Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25:839-46.
    • 5. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007;27:1177-83.
    • 6. O'Donoghue ML, Mallat Z, Morrow DA, et al. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem 2011;57:1311-7.
    • 7. Ryu SK, Mallat Z, Benessiano J, et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation 2012;125:757-66.
    • 8. Tietge UJ, Pratico D, Ding T, et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 2005;46:1604-14.
    • 9. Dzavik V, Lavi S, Thorpe K, et al. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDERPCI) trial. Circulation 2010;122:2411-8.
    • 10. Nicholls SJ, Cavender MA, Kastelein JJ, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial. Cardiovasc Drugs Ther 2012;26:71-5.
    • 11. Clinical Study Report for Study AN-CVD2233. Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects with Acute Coronary Syndromes. 2012. Available at: http://www.anthera. com/VISTA-16.pdf. Accessed September 2013.
    • 12. Snyder DW, Bach NJ, Dillard RD, et al. Pharmacology of LY315920/ S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4- yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther 1999;288:1117-24.
    • 13. Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009;53:60-5.
    • 14. Innocenti F, Cooper GM, Stanaway IB, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet 2011;7:e1002078.
    • 15. Wootton PT, Drenos F, Cooper JA, et al. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum Mol Genet 2006;15:355-61.
    • 16. Lawlor DA, Harbord RM, Sterne JA, Timpson N. Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63.
    • 17. Thompson JR, Minelli C, Abrams KR, Tobin MD, Riley RD. Metaanalysis of genetic studies using Mendelian randomizationda multivariate approach. Stat Med 2005;24:2241-54.
    • 18. Thomas DC, Lawlor DA, Thompson JR. Re: estimation of bias in nongenetic observational studies using “Mendelian triangulation” by Bautista et al. Ann Epidemiol 2007;17:511-3.
    • 19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
    • 20. Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 2010; 56:1079-88.
    • 21. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3- glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebocontrolled trial. Lancet 2009;373:649-58.
    • 22. Rosenson RS, Elliott M, Stasiv Y, Hislop C. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J 2011;32:999-1005.
    • 23. Padmanabhan S, Newton-Cheh C, Dominiczak AF. Genetic basis of blood pressure and hypertension. Trends Genet 2012;28:397-408.
    • 24. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.
    • 25. Minelli C, Thompson JR, Tobin MD, Abrams KR. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol 2004;160:445-52.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Funded by projects

  • WT | Understanding the genetic ba...
  • RCUK | Centre for molecular-based...
  • NWO | NCHA Subsidiebesluit 2008-2012
  • NIH | Health behaviors over the a...
  • EC | PHASE
  • EC | FAD

Cite this article